A Novel Pipeline for Drug Repurposing for Bladder Cancer Based on Patients’ Omics Signatures

A Novel Pipeline for Drug Repurposing for Bladder Cancer Based on Patients’ Omics Signatures

Multi-omics signatures of patients with bladder cancer (BC) can guide the identification of known de-risked therapeutic compounds through drug repurposing, an approach not extensively explored yet. In this study, we target drug repurposing in the context of BC, driven by tissue omics signatures. To...

Full description

Bibliographic Details
Main Authors: Marika Mokou, Vasiliki Lygirou, Ioanna Angelioudaki, Nikolaos Paschalidis, Rafael Stroggilos, Maria Frantzi, Agnieszka Latosinska, Aristotelis Bamias, Michèle J. Hoffmann, Harald Mischak, Antonia Vlahou
Format: Article
Language:English
Published: MDPI AG 2020-11-01
Series:Cancers
Subjects:
bladder cancer
drug repurposing
CMap
omics
proteomic
signature
Online Access:https://www.mdpi.com/2072-6694/12/12/3519

Internet

https://www.mdpi.com/2072-6694/12/12/3519

Similar Items